Treatment of cachexia: an overview of recent developments (Q26851540)

language of work or name

1 reference

December 2014

1 reference

Journal of the American Medical Directors Association

published in

1 reference

volume

15

1 reference

issue

12

1 reference

page(s)

866-72

1 reference

Circulating estradiol and mortality in men with systolic chronic heart failure

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Clinical pharmacology of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cachexia as a major underestimated and unmet medical need: facts and numbers

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

1 reference

7 January 2021

l-carnitine and cancer cachexia: Clinical and experimental aspects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Myopenia-a new universal term for muscle wasting

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Erratum to: Wasting in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Molecular control of neuromuscular junction development

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Ursodeoxycholic acid treatment in a rat model of cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal c

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effect of sexual dimorphism on muscle strength in cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Is there a genetic cause of appetite loss?-an explorative study in 1,853 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Hypogonadism in male cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Molecular and cellular mechanisms of skeletal muscle atrophy: an update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cancer cachexia: impact, mechanisms and emerging treatments

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

From muscle wasting to sarcopenia and myopenia: update 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Research on cachexia, sarcopenia and skeletal muscle in cardiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cachexia as a major public health problem: frequent, costly, and deadly

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cachexia vs obesity: where is the real unmet clinical need?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Muscle wasting disease: a proposal for a new disease classification

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Osteosarcopenic obesity: the role of bone, muscle, and fat on health

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Are we closer to having drugs to treat muscle wasting disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Sarcopenia: describing rather than defining a condition

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Muscle wasting in heart failure: An overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cachexia: a new definition

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

A new look at an old drug for the treatment of cancer cachexia: megestrol acetate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

1 reference

7 January 2021

Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Sarcopenia with limited mobility: an international consensus

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Body weight, anorexia, and undernutrition in older people

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

A Phase II dose titration study of thalidomide for cancer-associated anorexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Mechanism and novel therapeutic approaches to wasting in chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Cardiac cachexia: a systematic overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Treatment of cachexia with ghrelin in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021

Pancreatic cancer cachexia: a review of mechanisms and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAMDA.2014.09.007

7 January 2021